The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of abiraterone acetate in the treatment of castration-resistant prostate cancer: Early results from the German compassionate-use program.
Carsten Henning Ohlmann
Consultant or Advisory Role - Janssen-Cilag
Honoraria - Janssen-Cilag
Michael Stöckle
No relevant relationships to disclose
David A. Pfister
No relevant relationships to disclose
Axel Heidenreich
No relevant relationships to disclose
Axel S. Merseburger
No relevant relationships to disclose
Markus Kuczyk
No relevant relationships to disclose
Lukas Manka
No relevant relationships to disclose
Peter Hammerer
No relevant relationships to disclose
Peter Albers
No relevant relationships to disclose
Christian Arsov
No relevant relationships to disclose
Margitta Retz
No relevant relationships to disclose
Jürgen E. Gschwend
No relevant relationships to disclose
Susan Feyerabend
No relevant relationships to disclose
Arnulf Stenzl
No relevant relationships to disclose
Severine Banek
No relevant relationships to disclose
Jan Marin
No relevant relationships to disclose
Jochen Gleissner
No relevant relationships to disclose
Manfred Wirth
No relevant relationships to disclose
Stefan Zastrow
No relevant relationships to disclose
Matthias Heck
No relevant relationships to disclose